Actos opened up to first generic competition in Japan
This article was originally published in Scrip
Executive Summary
330 products from 63 manufacturers have been awarded reimbursement prices in the latest listing of generic drugs in Japan, which marks the advent of the first such competition for Takeda's big-selling oral antidiabetic Actos (pioglitazone).